Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy

Z. Huskova, J. Knillova, Z. Kolar, J. Vrbkova, M. Kral, J. Bouchal

. 2020 ; 8 (6) : . [pub] 20200625

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21027859

Grantová podpora
15-28628A Ministerstvo Zdravotnictví Ceské Republiky
DRO (FNOl, 00098892) Ministerstvo Zdravotnictví Ceské Republiky
NV15-28628A MZ0 CEP - Centrální evidence projektů

The main advantage of urinary biomarkers is their noninvasive character and the ability to detect multifocal prostate cancer (CaP). We have previously implemented a quadruplex assay of urinary markers into clinical practice (PCA3, AMACR, TRPM8 and MSMB with KLK3 normalization). In this study, we aimed to validate it in a larger cohort with serum PSA 2.5-10 ng/mL and test other selected transcripts and clinical parameters, including the percentage of free prostate-specific antigen (PSA) (% free PSA) and inflammation. In the main cohort of 299 men, we tested the quadruplex transcripts. In a subset of 146 men, we analyzed additional transcripts (CD45, EPCAM, EZH2, Ki67, PA2G4, PSGR, RHOA and TBP). After a prostate massage, the urine was collected, RNA isolated from a cell sediment and qRT-PCR performed. Ct values of KLK3 (i.e., PSA) were strongly correlated with Ct values of other genes which play a role in CaP (i.e., PCA3, AMACR, TRPM8, MSMB and PSGR). AMACR, PCA3, TRPM8 and EZH2 mRNA expression, as well as % free PSA, were significantly different for BPH and CaP. The best combined model (% free PSA plus PCA3 and AMACR) achieved an AUC of 0.728 in the main cohort. In the subset of patients, the best AUC 0.753 was achieved for the combination of PCA3, % free PSA, EPCAM and PSGR. PCA3 mRNA was increased in patients with inflammation, however, this did not affect the stratification of patients indicated for prostate biopsy. In conclusion, the percentage of free PSA and urinary markers contribute to a more accurate indication for prostate biopsy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21027859
003      
CZ-PrNML
005      
20230117103258.0
007      
ta
008      
211103s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/biomedicines8060173 $2 doi
035    __
$a (PubMed)32630458
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Huskova, Zlata $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, 779 00 Olomouc, Czech Republic
245    14
$a The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy / $c Z. Huskova, J. Knillova, Z. Kolar, J. Vrbkova, M. Kral, J. Bouchal
520    9_
$a The main advantage of urinary biomarkers is their noninvasive character and the ability to detect multifocal prostate cancer (CaP). We have previously implemented a quadruplex assay of urinary markers into clinical practice (PCA3, AMACR, TRPM8 and MSMB with KLK3 normalization). In this study, we aimed to validate it in a larger cohort with serum PSA 2.5-10 ng/mL and test other selected transcripts and clinical parameters, including the percentage of free prostate-specific antigen (PSA) (% free PSA) and inflammation. In the main cohort of 299 men, we tested the quadruplex transcripts. In a subset of 146 men, we analyzed additional transcripts (CD45, EPCAM, EZH2, Ki67, PA2G4, PSGR, RHOA and TBP). After a prostate massage, the urine was collected, RNA isolated from a cell sediment and qRT-PCR performed. Ct values of KLK3 (i.e., PSA) were strongly correlated with Ct values of other genes which play a role in CaP (i.e., PCA3, AMACR, TRPM8, MSMB and PSGR). AMACR, PCA3, TRPM8 and EZH2 mRNA expression, as well as % free PSA, were significantly different for BPH and CaP. The best combined model (% free PSA plus PCA3 and AMACR) achieved an AUC of 0.728 in the main cohort. In the subset of patients, the best AUC 0.753 was achieved for the combination of PCA3, % free PSA, EPCAM and PSGR. PCA3 mRNA was increased in patients with inflammation, however, this did not affect the stratification of patients indicated for prostate biopsy. In conclusion, the percentage of free PSA and urinary markers contribute to a more accurate indication for prostate biopsy.
650    17
$a nádory prostaty $x diagnóza $7 D011471 $2 czmesh
650    _7
$a hyperplazie prostaty $7 D011470 $2 czmesh
650    _7
$a časná detekce nádoru $x metody $7 D055088 $2 czmesh
650    17
$a nádorové biomarkery $x moč $7 D014408 $2 czmesh
650    _7
$a biopsie $7 D001706 $2 czmesh
650    _7
$a prostatický specifický antigen $x moč $7 D017430 $2 czmesh
650    _7
$a zánět $7 D007249 $2 czmesh
650    _7
$a analýza moči $x metody $7 D016482 $2 czmesh
650    _7
$a lidé $7 D006801 $2 czmesh
650    _7
$a mužské pohlaví $7 D008297 $2 czmesh
655    _2
$a časopisecké články $7 D016428
655    _7
$a práce podpořená grantem $7 D013485 $2 czmesh
700    1_
$a Knillová, Jana $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, 779 00 Olomouc, Czech Republic $7 xx0098127
700    1_
$a Kolář, Zdeněk, $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, 779 00 Olomouc, Czech Republic $d 1953- $7 jn20000710256
700    1_
$a Vrbková, Jana $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic $7 _AN085567
700    1_
$a Král, Milan $u Department of Urology, University Hospital, 779 00 Olomouc, Czech Republic $7 xx0079094
700    1_
$a Bouchal, Jan, $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, 779 00 Olomouc, Czech Republic $d 1973- $7 xx0034399
773    0_
$w MED00205373 $t Biomedicines $x 2227-9059 $g Roč. 8, č. 6 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32630458 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211103 $b ABA008
991    __
$a 20230117103254 $b ABA008
999    __
$a kom $b bmc $g 1718483 $s 1148390
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 8 $c 6 $e 20200625 $i 2227-9059 $m Biomedicines $n Biomedicines $x MED00205373
GRA    __
$a 15-28628A $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a DRO (FNOl, 00098892) $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a NV15-28628A $p MZ0
LZP    __
$c NLK120 $d 20230117 $a 2021-granty

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...